Landcadia Holdings IV, Inc.

    Landcadia Holdings IV, Inc.

    NNASDAQ:LCA
    10.54
    USD
    0.00
    (0.00%)
    No data availableFinancial data will appear here once available

    Capital Structure

    FRC

    •

    in mil. unless spec.
    No data availableFinancial data will appear here once available

    Working Capital

    FRC

    •

    in mil. unless spec.
    No data availableFinancial data will appear here once available

    Growth Rates

    FRC

    •

    in mil. unless spec.
    No data availableFinancial data will appear here once available

    Quarterly Revenue

    FRC

    •

    in mil. unless spec.
    No data availableFinancial data will appear here once available

    Quarterly Earnings Per Share

    FRC

    •

    in mil. unless spec.
    No data availableFinancial data will appear here once available

    Quarterly Dividends Per Share

    FRC

    •

    in mil. unless spec.
    No data availableFinancial data will appear here once available

    Company Description

    Address
    Similar Companies
    Business

    Company News

    • Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease

    • Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Disease

    • Vontier Surpasses 2030 Emissions Target Five Years Early, Sets New 65% Reduction Goal

    • Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program

    • Opus Genetics: Asymmetric Upside With LCA5 And BEST1

    • Beyond Meat® Releases 2024 Corporate Responsibility Report and LCA Study that Estimates Environmental Benefits of Beyond Burger® IV, Submits to CDP for First Time

    • Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease

    • Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)

    • Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate

    • Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision

    • Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases

    • Opus Genetics Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

    • Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program

    • Beyond Meat® Releases 2023 ESG Report and LCA Study that Estimates Environmental Benefits of Beyond Steak® Plant-Based Seared Tips When Compared to Pre-Cooked Beef-Based Steak Tips

    • Segway-Ninebot Goes Green with Electric KickScooters and More Sustainable Practices

    • Last Chance for Animals, Animal Liberation Wave Undercover Investigation Unveils More Atrocities in South Korean Dog Meat Trade

    • Life Cycle Assessment (LCA) Study in India Shows that Aluminium Beverage Cans have Superior Environmental Performance over Glass, PET and Multi-layer Drinks Containers

    • Landcadia Holdings III, Inc. (LCY) CEO Doug Cahill on Q1 2021 Results - Earnings Call Transcript

    • SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Landcadia Holdings III, Inc. - LCY

    • A Smooth Transition Is Great News For Landcadia Holdings II